The following drugs have been approved since the year 2000 for the treatment of non-Hodgkin's lymphoma:
FDA approved October 2008
Bendamustine is a chemotherapy drug approved for the treatment of B-cell non-Hodgkin lymphomas.
FDA approved October 2005
This chemotherapy drug is approved for the treatment of T-cell lymphoblastic lymphoma.
FDA approved June 2003
This drug is a monoclonal antibody that targets specific lymphoma cells. Tositumomab is linked to a radioactive agent called iodine-131 (I-131). The medicine allows radiation to be delivered directly to the sites of the lymphoma.
Zevalin (ibritumomab tiuxetan)
FDA approved February 2002
This drug is a protein that targets specific lymphoma cells. To be effective ibritumomab tiuxetan is linked to a radioactive agent called yttrium chloride (Y-90). The medicine allows radiation to be delivered directly to the sites of the lymphoma.